Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 18 '25)

Image
By G.M.

 


    Antiviral Res

  1. PATEL MC, Nguyen HT, Mishin VP, Pascua PNQ, et al
    Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023-2024.
    Antiviral Res. 2025 Oct 11:106299. doi: 10.1016/j.antiviral.2025.106299.
    PubMed         Abstract available

  2. ZHU C, Wang Z, Pan Z, Mai X, et al
    DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection.
    Antiviral Res. 2025 Sep 3:106269. doi: 10.1016/j.antiviral.2025.106269.
    PubMed         Abstract available

  3. TASHIMA R, Kuroda T, Nobori H, Miyagawa S, et al
    Ensitrelvir suppresses prolonged olfactory abnormalities derived from SARS-CoV-2 infection in hamsters.
    Antiviral Res. 2025 Sep 2:106270. doi: 10.1016/j.antiviral.2025.106270.
    PubMed         Abstract available


    BMC Pediatr

  4. WU LE, Wei JY, Lin ZH, Li HC, et al
    Clinical characteristics of children with idiopathic nephrotic syndrome infected with SARS-CoV-2: a single-center retrospective cohort study.
    BMC Pediatr. 2025;25:803.
    PubMed         Abstract available


    J Infect Dis

  5. HENAUT M, Carbonneau J, Levade I, Boivin G, et al
    Fitness of SARS-CoV-2 Omicron Subvariants in Respiratory and Gastrointestinal Cell Lines as Determined by Reverse-Transcription Droplet Digital PCR and Whole-Genome Sequencing.
    J Infect Dis. 2025;232:e656-e660.
    PubMed         Abstract available

  6. KITTIKRAISAK W, Mohanty S, Klungthong C, Macareo L, et al
    Antenatal Respiratory Syncytial Virus and Human Metapneumovirus Illness Rates Among Pregnant Women in Thailand and the Association Between Antenatal Respiratory Syncytial Virus and Perinatal Outcomes: A Prospective Cohort Study.
    J Infect Dis. 2025;232:e651-e655.
    PubMed         Abstract available

  7. ATMAR RL, Lyke KE, Posavad CM, Deming ME, et al
    Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    J Infect Dis. 2025 Apr 29:jiaf176. doi: 10.1093.
    PubMed         Abstract available

  8. JIANG D, Hurst JH, Mohamed G, Kelly MS, et al
    Decreased Microbiota-Driven Tyrosine Metabolism Is Associated With Symptomatic COVID-19 in Children.
    J Infect Dis. 2025;232:796-805.
    PubMed         Abstract available

  9. SAMANDARI T, Achola M, Hutter JN, Mboya G, et al
    Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
    J Infect Dis. 2025 Aug 2:jiaf398. doi: 10.1093.
    PubMed         Abstract available

  10. BUI VL, Ragonnet R, Hughes AE, Shipman DS, et al
    Impact of Case Detection and Covid-19-Related Disruptions on Tuberculosis In Vietnam: A Modelling Analysis.
    J Infect Dis. 2025 Aug 7:jiaf406. doi: 10.1093.
    PubMed         Abstract available

  11. WAITE AAC, Peto L, Gordon AC, Horby P, et al
    Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  12. BRIGHT RA
    Optimizing Antiviral Stockpiles for Pandemic Response: A Strategic Framework.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  13. SHINDO N, Huvos A, Nguyen T
    Evolution of WHO Influenza Antiviral Stockpile: Rapid Access and Use in Low- and Middle-Income Countries for Pandemic Preparedness and Response.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  14. HAYDEN FG, Whitley RJ
    Introduction and Update: Advances in Influenza Therapeutics.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  15. LEE K, Pavia AT, Englund JA
    Improving Access to Influenza Testing and Treatment: Is It Time for Over-the-counter Oseltamivir?
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  16. TAKASHITA E, Wolfe CR, Jones JC
    Laboratory Methods for Monitoring Influenza Antiviral Resistance.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  17. DAMHORST GL, Lam WA
    Point-of-care and Home Use Influenza Diagnostics for Advancing Therapeutic and Public Health Strategies.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  18. ZAMBON M, Myles P, Sugaya N
    Use of Influenza Antivirals in Pandemic Response.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  19. BEIGEL JH, Oldach D
    Polyclonal and Monoclonal Antibodies for the Treatment and Prevention of Influenza.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  20. HASTINGS LE, Acosta EP, Kimberlin DW
    Influenza Antiviral Pharmacokinetic-Pharmacodynamic Relationships in Pregnancy, Infancy, and Early Childhood.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  21. KARAKONSTANTIS S, Lytras T, Keske S, Tsiodras S, et al
    The Care Continuum of Patients With Influenza in the Post-COVID-19 Era: A Position Paper.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  22. HELDMAN MR, Boeckh MJ, Ison MG
    Influenza Antivirals for Prevention and Treatment in Immunocompromised People.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  23. COWLING BJ, Lin Y, Ikematsu H
    Use of Influenza Antivirals to Prevent Transmission.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  24. PASCO R, Hayden FG, Meyers LA
    Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  25. LI J, Jin Y, Wang Y, Shang L, et al
    New Developments in Influenza Polymerase Inhibitors.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  26. UYEKI TM, Belser JA
    Antivirals for Novel Influenza A Virus Infections.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  27. HUI DSC, Chan KKP
    Host Immunomodulatory Interventions in Severe Influenza.
    J Infect Dis. 2025;232.
    PubMed         Abstract available


    PLoS Comput Biol

  28. JOUBBI S, Micheli A, Milazzo P, Ciano G, et al
    Enhancing antibody-antigen interaction prediction with atomic flexibility.
    PLoS Comput Biol. 2025;21:e1013576.
    PubMed         Abstract available

  29. ERANTI P, Hegde M, Al Sium SM, Parra RG, et al
    Impact of the COVID-19 pandemic on computational biology early career researchers: A global retrospective study.
    PLoS Comput Biol. 2025;21:e1013554.
    PubMed         Abstract available

  30. TORRAS-PEREZ M, Yoon IHR, Weeratunga P, Ho LP, et al
    Topology across scales on heterogeneous cell data.
    PLoS Comput Biol. 2025;21:e1013460.
    PubMed         Abstract available


    PLoS Med

  31. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
    Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
    PLoS Med. 2025;22:e1004499.
    PubMed         Abstract available


    PLoS One

  32. RISNER M, Hu L, Stamoulis C
    Pre-pandemic mental health and brain characteristics predict adolescent stress and emotions during the COVID-19 pandemic.
    PLoS One. 2025;20:e0334028.
    PubMed         Abstract available

  33. HADAYA J, Ebrahimian S, Cho NY, Kim S, et al
    Trends and outcomes of cardiac arrest and extracorporeal membrane oxygenation during the COVID-19 pandemic in the United States.
    PLoS One. 2025;20:e0334896.
    PubMed         Abstract available

  34. MAGBOR P, Wang WZ, Gugan G, Olabode AS, et al
    Spatiotemporal structure of SARS-CoV-2 mutational frequencies in wastewater samples from Ontario.
    PLoS One. 2025;20:e0333945.
    PubMed         Abstract available

  35. DUBUIS ME, Racine E, Vyskocil JM, Turgeon N, et al
    Correction: Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes.
    PLoS One. 2025;20:e0334842.
    PubMed         Abstract available

  36. WAGELAAR EM, Hogeveen LS, Jonkman NH, Bakker A, et al
    Healthcare employees' perspectives on organizational communication about preventive mental health interventions: A focus group study.
    PLoS One. 2025;20:e0334716.
    PubMed         Abstract available

  37. ELLEGAARD KM, Gunalan V, Sieber R, Baig SJ, et al
    SARS-CoV-2 sequencing artifacts associated with targeted PCR enrichment and read mapping.
    PLoS One. 2025;20:e0334009.
    PubMed         Abstract available

  38. SHAKEEL I, Rashid HB, Ain QU, Inayat A, et al
    Prevalence and risk factors of Influenza Avian Virus in backyard pigeons, ducks, and chickens in Toba Tek Singh District, Pakistan.
    PLoS One. 2025;20:e0314186.
    PubMed         Abstract available

  39. NAGRA G, Ezeugwu VE, Bostick GP, Branton E, et al
    Return-to-work for people living with long COVID: A scoping review of interventions and recommendations.
    PLoS One. 2025;20:e0321891.
    PubMed         Abstract available

  40. MEJIA GOMEZ LA, Menendez D, Umscheid V, Gelman SA, et al
    Who gets sicker and why? Parents' perceptions of COVID-19 disparities and how they would explain them to their children.
    PLoS One. 2025;20:e0332140.
    PubMed         Abstract available

  41. HOSSEN MT, Alam MSB, Islam MS, Montomoli E, et al
    Impact of the COVID-19 pandemic on the routine immunization system in Bangladesh.
    PLoS One. 2025;20:e0334503.
    PubMed         Abstract available

  42. WENG PY, Li D, Liao ML, Chiang YC, et al
    Aging in rural communities: Engagement in indoor leisure activities and older adult health.
    PLoS One. 2025;20:e0334111.
    PubMed         Abstract available

  43. GAO F, Wang D, Zuo L, Sun J, et al
    Alterations in the serum metabolome in patients with the COVID-19 Omicron variant and in recovered cases.
    PLoS One. 2025;20:e0327297.
    PubMed         Abstract available

  44. CHICOINE N, Griffin J
    The unreliability of estimated release dates in hospital drug shortage management: A case study of hospital pharmacy operations during the COVID-19 pandemic.
    PLoS One. 2025;20:e0328747.
    PubMed         Abstract available


    Vaccine

  45. PIRES C
    Influenza vaccine hesitancy in the elderly: Where do we stand?
    Vaccine. 2025;66:127831.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »